Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immuneering Corporation (IMRX : NSDQ)

• Company Description    Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass. Number of Employees: 66

• Price / Volume Information    Yesterday's Closing Price: $8.49 Daily Weekly Monthly 20 Day Moving Average: 1,213,473 shares Shares Outstanding: 41.57 (millions) Market Capitalization: $352.93 (millions) Beta: 0.43 52 Week High: $9.37 52 Week Low: $1.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 179.28% 174.37% 12 Week 206.50% 178.41% Year To Date 285.91% 233.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 245 MAIN STREET SECOND FLOOR - CAMBRIDGE,MA 02142 USA ph: 617-500-8080 fax: - ir@immuneering.com http://www.immuneering.com

• General Corporate Information    Officers Benjamin J. Zeskind - Chief Executive Officer; President and Director Mallory Morales - Chief Accounting Officer and Treasurer Ann E. Berman - Director Robert J. Carpenter - Director Peter Feinberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45254E107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 41.57 Most Recent Split Date: (:1) Beta: 0.43 Market Capitalization: $352.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.56 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 14.89% vs. Previous Quarter: 4.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -146.28 03/31/25 - -119.22 12/31/24 - -100.00 ROA 06/30/25 - -117.22 03/31/25 - -99.22 12/31/24 - -85.26 Current Ratio 06/30/25 - 3.70 03/31/25 - 7.48 12/31/24 - 5.28 Quick Ratio 06/30/25 - 3.70 03/31/25 - 7.48 12/31/24 - 5.28 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.80 03/31/25 - 1.16 12/31/24 - 1.33 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©